More than half of all American adults, almost 137 million people, could be candidates for the blockbuster GLP-1 drug ...

Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers published in JACC, the flagship journal of the American College of Cardiology, ...

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking ...

Reducing systolic blood pressure to less than 120 mmHg lowered the risk of major cardiovascular events for most people with ...

Heart Disease and Diabetes People with diabetes are much more likely to ... Regular blood and urine tests to check for kidney ...

While coronary heart disease and diabetes are often seen in the same patients ... that we should be focusing on other proven interventions for people with diabetes, like medication management, diet ...

The best diabetes medication if you have kidney disease can vary by the severity ... high blood pressure, heart problems, and more. When patients have chronic kidney disease, the kidneys aren ...

People with both type 2 diabetes and chronic kidney disease face a heart health double-whammy, a new study says.

SUMMT has shown for the first time that a drug can reduce major heart failure clinical outcomes in patients with heart ...

At AHA 2024, the safety of GLP-1R agonists in heart failure and chronic kidney disease (CKD) patients was discussed.

Real-world data show reduction in use of urate-lowering therapy among people with type 2 diabetes using SGLT2 inhibitors.